Katherine Moxley

38.5k total citations · 1 hit paper
71 papers, 2.0k citations indexed

About

Katherine Moxley is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Katherine Moxley has authored 71 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Obstetrics and Gynecology, 28 papers in Reproductive Medicine and 18 papers in Molecular Biology. Recurrent topics in Katherine Moxley's work include Endometrial and Cervical Cancer Treatments (27 papers), Ovarian cancer diagnosis and treatment (25 papers) and Uterine Myomas and Treatments (8 papers). Katherine Moxley is often cited by papers focused on Endometrial and Cervical Cancer Treatments (27 papers), Ovarian cancer diagnosis and treatment (25 papers) and Uterine Myomas and Treatments (8 papers). Katherine Moxley collaborates with scholars based in United States, South Korea and Italy. Katherine Moxley's co-authors include D. Scott McMeekin, Danny N. Dhanasekaran, David M. O’Malley, Joan L. Walker, Virginia L. Filiaci, David G. Mutch, Akhil Srivastava, Rajagopal Ramesh, Krishnansu S. Tewari and David S. Miller and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Katherine Moxley

67 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

2019 289 citations Daniela Matei, Virginia L. Filiaci et al. profile →

Peers

Countries citing papers authored by Katherine Moxley

Since Specialization

Citations

This map shows the geographic impact of Katherine Moxley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Moxley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Moxley more than expected).

Fields of papers citing papers by Katherine Moxley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Moxley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Moxley. The network helps show where Katherine Moxley may publish in the future.

Co-authorship network of co-authors of Katherine Moxley

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Moxley. A scholar is included among the top collaborators of Katherine Moxley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Moxley. Katherine Moxley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer 2024 ·Gynecologic Oncology ·(unknown), Samrita Dogra, (unknown), M. Iqbal Parker, Amy E. Kennedy, Doris M. Benbrook, Katherine Moxley, Bethany N. Hannafon	1
2	Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer 2023 ·Cancer Letters ·Samrita Dogra, (unknown), Dongfeng Qu, (unknown), Alexander Filatenkov, Courtney W. Houchen, William L. Berry, Katherine Moxley, Bethany N. Hannafon	13
3	TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study 2022 ·Journal of Clinical Oncology ·Kristina W. Thiel, Eric J. Devor, Virginia L. Filiaci, David G. Mutch, Katherine Moxley, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Carol Aghajanian, Megan I. Samuelson, Heather A. Lankes, Robert A. Soslow, Kimberly K. Leslie	45
4	A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium 2022 ·Gynecologic Oncology ·(unknown), Kathleen N. Moore, Leigh A. Cantrell, Britt Erickson, Linda Duska, Debra L. Richardson, Lisa M. Landrum, Laura L. Holman, Joan L. Walker, Robert S. Mannel, Katherine Moxley, Lurdes Queimado, Andrew J. Cohoon, Kai Ding, (unknown)	10
5	Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study 2021 ·Gynecologic Oncology ·Ursula A. Matulonis, Helen Huang, Virginia L. Filiaci, Marcus E. Randall, Paul DiSilvestro, Katherine Moxley, Jeffrey M. Fowler, Matthew A. Powell, Nick M. Spirtos, Krishnansu S. Tewari, William E. Richards, John Nakayama, David G. Mutch, David S. Miller, Daniela Matei, Lari Wenzel	4
6	Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) 2020 ·Clinical Cancer Research ·Diane M. Da Silva, Danielle Enserro, Jyoti Mayadev, Joseph G. Skeate, Koji Matsuo, Huyen Q. Pham, Heather A. Lankes, Katherine Moxley, Sharad Ghamande, Yvonne G. Lin, Russell J. Schilder, Michael J. Birrer, W. Martin Kast	54
7	An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275 2020 ·Gynecologic Oncology ·Julian C. Schink, Virginia L. Filiaci, Helen Huang, John Tidy, Matthew Winter, Jeanne Carter, Nancy Anderson, Katherine Moxley, Akira Yabuno, Sarah E. Taylor, (unknown), Neil S. Horowitz, David S. Miller	23
8	GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study 2019 ·Gynecologic Oncology ·Rebecca Brooks, David Tritchler, Kathleen M. Darcy, Heather A. Lankes, Ritu Salani, Paul W. Sperduto, Saketh R. Guntupalli, Paul DiSilvestro, Joshua P. Kesterson, Alexander Olawaiye, Katherine Moxley, Steven Waggoner, Alessandro D. Santin, Janet S. Rader, Nora T. Kizer, Premal H. Thaker, Matthew A. Powell, David G. Mutch, Michael J. Birrer, Paul J. Goodfellow	5
9	LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response 2018 ·Cancer Research ·Ji Hee Ha, Rangasudhagar Radhakrishnan, Muralidharan Jayaraman, Mingda Yan, Jeremy D. Ward, Kar‐Ming Fung, Katherine Moxley, Anil K. Sood, Ciro Isidoro, Priyabrata Mukherjee, Yong Sang Song, Danny N. Dhanasekaran	68
10	Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts 2018 ·Cancer Letters ·Rangasudhagar Radhakrishnan, Ji Hee Ha, Muralidharan Jayaraman, Jinsong Liu, Katherine Moxley, Ciro Isidoro, Anil K. Sood, Yong Sang Song, Danny N. Dhanasekaran	92
11	A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study 2018 ·Gynecologic Oncology ·Bradley J. Monk, James Kauderer, Katherine Moxley, Albert J. Bonebrake, Summer Dewdney, Angeles Alvarez Secord, Frederick R. Ueland, Carolyn M. Johnston, Carol Aghajanian	65
12	Classification of Tumor Epithelium and Stroma by Exploiting Image Features Learned by Deep Convolutional Neural Networks 2018 ·Annals of Biomedical Engineering ·(unknown), Roy Zhang, (unknown), Theresa Thai, Camille C. Gunderson, Katherine Moxley, Hong Liu, Bin Zheng, Yuchen Qiu	57
13	Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study 2017 ·Gynecologic Oncology ·David E. Cohn, Michael W. Sill, Joan L. Walker, David M. O’Malley, Christa Nagel, Teresa Rutledge, William H. Bradley, Debra L. Richardson, Katherine Moxley, Carol Aghajanian	61
14	Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy 2017 ·Academic Radiology ·Gopichandh Danala, Theresa Thai, Camille C. Gunderson, Katherine Moxley, Kathleen N. Moore, Robert S. Mannel, Hong Liu, Bin Zheng, Yuchen Qiu	36
15	Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial 2016 ·Gynecologic Oncology ·Eric D. Thomas, Elizabeth Nugent, (unknown), Katherine Moxley, Lisa M. Landrum, Joan L. Walker, (unknown), Robert S. Mannel, Gerald McGwin, Kathleen N. Moore	3
16	Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment 2015 ·Current Gene Therapy ·Akhil Srivastava, Justyna Filant, Katherine Moxley, Anil K. Sood, Scott McMeekin, Rajagopal Ramesh	75
17	IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells 2015 ·Cancer Gene Therapy ·(unknown), Samantha Suriano, (unknown), (unknown), Pravin Kesarwani, (unknown), Katherine Moxley, Mohamed L. Salem, Elizabeth Garrett‐Mayer, Chrystal M. Paulos, Shikhar Mehrotra, James N. Kochenderfer, David J. Cole, Mark P. Rubinstein	8
18	The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer 2013 ·Gynecologic Oncology ·Katherine Moxley, Doris M. Benbrook, Lurdes Queimado, Rosemary E. Zuna, David M. Thompson, Micah McCumber, Prasanna Samuel Premkumar, Elangovan Thavathiru, Lisa M. Hines, (unknown)	18
19	Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents 2009 ·Gynecologic Oncology ·Katherine Moxley, (unknown), (unknown)	18
20	Resolution of Hydrops Secondary to Cytomegalovirus After Maternal and Fetal Treatment With Human Cytomegalovirus Hyperimmune Globulin 2008 ·Obstetrics and Gynecology ·Katherine Moxley, Eric Knudtson	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact